No Data
No Data
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Inhibikase Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Inhibikase Therapeutics Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/21/2024 1170.72% HC Wainwright & Co. $27 → $23 Maintains Buy 03/07/2024 1391.71% HC Wainwright & Co. →
Analysts Offer Insights on Healthcare Companies: Evolus (EOLS), Korro Bio (KRRO) and Inhibikase Therapeutics (IKT)
Express News | Inhibikase Therapeutics, Inc. : H.c. Wainwright Cuts Target Price to $23 From $27
Express News | Inhibikase Therapeutics Prices $4.0M Registered Direct Offering And Warrant Inducement Of 1,672,452 Shares Of Common Stock And 1,672,452 Unregisted Class B Warrants At Combined Purchase Price Of $1.68 Per Common Stock And Series A And B Warrant
Express News | Inhibikase Therapeutics- Entered a Securities Purchase Agreement With a Single Institutional Investor to Purchase 1.7 Mln Shares of Common Stock
No Data